APO RESEARCH · REPORT
Acute Migraine Drugs
A migraine is an episodic and unpredictable headache disorder that presents with disabling attack. Migraine is one of the most frequent disabling neurological conditions with a major impact on the patient’s quality of life. Migraine has been described as a chronic disorder that characterized with attacks. Attacks are characterized by moderate–severe, often unilateral, pulsating headache attacks, typically lasting 4 to 72 hours.
Product & engineering
Understand the product.
A migraine is an episodic and unpredictable headache disorder that presents with disabling attack. Migraine is one of the most frequent disabling neurological conditions with a major impact on the patient’s quality of life. Migraine has been described as a chronic disorder that characterized with attacks. Attacks are characterized by moderate–severe, often unilateral, pulsating headache attacks, typically lasting 4 to 72 hours.
Selected research
Market Structure
Global Acute Migraine Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
A migraine is an episodic and unpredictable headache disorder that presents with disabling attack. Migraine is one of the most frequent disabling neurological conditions with a major impact on the patient’s quality of life. Migraine has been described as a chronic disorder that characterized with attacks. Attacks are characterized by moderate–severe, often unilateral, pulsating headache attacks, typically lasting 4 to 72 hours.
The top 3 manufacturers held about 29.5% of the market share in 2019, while top 5 hold 41.93%.
This report provides an overview of the global Acute Migraine Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
Read the full market overview
The study covers key producers of Acute Migraine Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Acute Migraine Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Acute Migraine Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Acute Migraine Drugs Segment by Company
GSK
Teva
Pfizer
Novartis
Sun Pharma
Grunenthal
Endo Pharmaceuticals
Merck
J & J
Acute Migraine Drugs Segment by Type
Triptans
NSAIDs
Others
Acute Migraine Drugs Segment by Application
Hospital Pharmacies
Drug Stores
Acute Migraine Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Migraine Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Acute Migraine Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Migraine Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Acute Migraine Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acute Migraine Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Acute Migraine Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Acute Migraine Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Triptans
- NSAIDs
- Others
Applications
- Hospital Pharmacies
- Drug Stores
Companies covered
- GSK
- Teva
- Pfizer
- Novartis
- Sun Pharma
- Grunenthal
- Endo Pharmaceuticals
- Merck
- J & J
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Acute Migraine Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Acute Migraine Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Acute Migraine Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Acute Migraine Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Acute Migraine Drugs Market Dynamics
- 2.1 Acute Migraine Drugs Industry Trends
- 2.2 Acute Migraine Drugs Industry Drivers
- 2.3 Acute Migraine Drugs Industry Opportunities and Challenges
- 2.4 Acute Migraine Drugs Industry Restraints
3 Acute Migraine Drugs Market by Manufacturers
- 3.1 Global Acute Migraine Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Acute Migraine Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Acute Migraine Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Acute Migraine Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Acute Migraine Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Acute Migraine Drugs Manufacturers, Product Type & Application
- 3.7 Global Acute Migraine Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Acute Migraine Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Acute Migraine Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Acute Migraine Drugs Tier 1, Tier 2, and Tier 3
4 Acute Migraine Drugs Market by Type
- 4.1 Acute Migraine Drugs Type Introduction
- 4.1.1 Triptans
- 4.1.2 NSAIDs
- 4.1.3 Others
- 4.2 Global Acute Migraine Drugs Sales by Type
- 4.2.1 Global Acute Migraine Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Acute Migraine Drugs Sales by Type (2021-2032)
- 4.2.3 Global Acute Migraine Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Acute Migraine Drugs Revenue by Type
- 4.3.1 Global Acute Migraine Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Acute Migraine Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Acute Migraine Drugs Revenue Market Share by Type (2021-2032)
5 Acute Migraine Drugs Market by Application
- 5.1 Acute Migraine Drugs Application Introduction
- 5.1.1 Hospital Pharmacies
- 5.1.2 Drug Stores
- 5.2 Global Acute Migraine Drugs Sales by Application
- 5.2.1 Global Acute Migraine Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Acute Migraine Drugs Sales by Application (2021-2032)
- 5.2.3 Global Acute Migraine Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Acute Migraine Drugs Revenue by Application
- 5.3.1 Global Acute Migraine Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Acute Migraine Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Acute Migraine Drugs Revenue Market Share by Application (2021-2032)
6 Global Acute Migraine Drugs Sales by Region
- 6.1 Global Acute Migraine Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Acute Migraine Drugs Sales by Region (2021-2032)
- 6.2.1 Global Acute Migraine Drugs Sales by Region (2021-2026)
- 6.2.2 Global Acute Migraine Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Acute Migraine Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Acute Migraine Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Acute Migraine Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Acute Migraine Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Acute Migraine Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Acute Migraine Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Acute Migraine Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Acute Migraine Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Acute Migraine Drugs Revenue by Region
- 7.1 Global Acute Migraine Drugs Revenue by Region
- 7.1.1 Global Acute Migraine Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Acute Migraine Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Acute Migraine Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Acute Migraine Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Acute Migraine Drugs Revenue (2021-2032)
- 7.2.2 North America Acute Migraine Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Acute Migraine Drugs Revenue (2021-2032)
- 7.3.2 Europe Acute Migraine Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Acute Migraine Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Acute Migraine Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Acute Migraine Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Acute Migraine Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 GSK
- 8.1.1 GSK Company Information
- 8.1.2 GSK Business Overview
- 8.1.3 GSK Acute Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 GSK Acute Migraine Drugs Product Portfolio
- 8.1.5 GSK Recent Developments
- 8.2 Teva
- 8.2.1 Teva Company Information
- 8.2.2 Teva Business Overview
- 8.2.3 Teva Acute Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Teva Acute Migraine Drugs Product Portfolio
- 8.2.5 Teva Recent Developments
- 8.3 Pfizer
- 8.3.1 Pfizer Company Information
- 8.3.2 Pfizer Business Overview
- 8.3.3 Pfizer Acute Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Pfizer Acute Migraine Drugs Product Portfolio
- 8.3.5 Pfizer Recent Developments
- 8.4 Novartis
- 8.4.1 Novartis Company Information
- 8.4.2 Novartis Business Overview
- 8.4.3 Novartis Acute Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Novartis Acute Migraine Drugs Product Portfolio
- 8.4.5 Novartis Recent Developments
- 8.5 Sun Pharma
- 8.5.1 Sun Pharma Company Information
- 8.5.2 Sun Pharma Business Overview
- 8.5.3 Sun Pharma Acute Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Sun Pharma Acute Migraine Drugs Product Portfolio
- 8.5.5 Sun Pharma Recent Developments
- 8.6 Grunenthal
- 8.6.1 Grunenthal Company Information
- 8.6.2 Grunenthal Business Overview
- 8.6.3 Grunenthal Acute Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Grunenthal Acute Migraine Drugs Product Portfolio
- 8.6.5 Grunenthal Recent Developments
- 8.7 Endo Pharmaceuticals
- 8.7.1 Endo Pharmaceuticals Company Information
- 8.7.2 Endo Pharmaceuticals Business Overview
- 8.7.3 Endo Pharmaceuticals Acute Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Endo Pharmaceuticals Acute Migraine Drugs Product Portfolio
- 8.7.5 Endo Pharmaceuticals Recent Developments
- 8.8 Merck
- 8.8.1 Merck Company Information
- 8.8.2 Merck Business Overview
- 8.8.3 Merck Acute Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Merck Acute Migraine Drugs Product Portfolio
- 8.8.5 Merck Recent Developments
- 8.9 J & J
- 8.9.1 J & J Company Information
- 8.9.2 J & J Business Overview
- 8.9.3 J & J Acute Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 J & J Acute Migraine Drugs Product Portfolio
- 8.9.5 J & J Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Acute Migraine Drugs Value Chain Analysis
- 9.1.1 Acute Migraine Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Acute Migraine Drugs Production Mode & Process
- 9.2 Acute Migraine Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Acute Migraine Drugs Distributors
- 9.2.3 Acute Migraine Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst